Guidance Capital Inc. purchased a new stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 32,030 shares of the medical research company's stock, valued at approximately $528,000.
Other large investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of NeoGenomics by 1.6% during the third quarter. State Street Corp now owns 4,958,582 shares of the medical research company's stock worth $73,139,000 after buying an additional 80,449 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of NeoGenomics by 1.2% in the third quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company's stock valued at $45,022,000 after purchasing an additional 36,136 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of NeoGenomics by 2.0% in the third quarter. Franklin Resources Inc. now owns 2,043,840 shares of the medical research company's stock valued at $28,225,000 after purchasing an additional 39,740 shares in the last quarter. Segall Bryant & Hamill LLC raised its stake in shares of NeoGenomics by 67.0% in the third quarter. Segall Bryant & Hamill LLC now owns 1,893,407 shares of the medical research company's stock valued at $27,928,000 after purchasing an additional 759,524 shares in the last quarter. Finally, Bellevue Group AG raised its stake in shares of NeoGenomics by 34.2% in the third quarter. Bellevue Group AG now owns 1,612,612 shares of the medical research company's stock valued at $23,786,000 after purchasing an additional 410,516 shares in the last quarter. Institutional investors own 98.50% of the company's stock.
Insider Activity at NeoGenomics
In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the firm's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the transaction, the general counsel now owns 37,129 shares in the company, valued at $570,301.44. This trade represents a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by company insiders.
NeoGenomics Price Performance
Shares of NEO stock traded down $0.04 during trading hours on Friday, hitting $13.45. 557,510 shares of the company's stock were exchanged, compared to its average volume of 1,185,407. The stock's 50-day moving average is $16.09 and its 200-day moving average is $15.65. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.99 and a quick ratio of 1.91. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -22.05 and a beta of 1.23. NeoGenomics, Inc. has a 52 week low of $12.13 and a 52 week high of $19.11.
NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. The company had revenue of $167.80 million for the quarter, compared to analysts' expectations of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The business's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.06) earnings per share. As a group, research analysts forecast that NeoGenomics, Inc. will post -0.16 EPS for the current year.
Wall Street Analyst Weigh In
NEO has been the subject of a number of recent research reports. Bank of America upped their target price on NeoGenomics from $18.00 to $19.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. Jefferies Financial Group began coverage on NeoGenomics in a research report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 price target on the stock. The Goldman Sachs Group lowered their price target on NeoGenomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Needham & Company LLC reiterated a "buy" rating and issued a $19.00 price target on shares of NeoGenomics in a research report on Friday, January 10th. Finally, Benchmark cut NeoGenomics from a "buy" rating to a "hold" rating in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, NeoGenomics has a consensus rating of "Moderate Buy" and a consensus price target of $20.20.
Read Our Latest Analysis on NEO
NeoGenomics Company Profile
(
Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Further Reading
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
